Sanjay Smith, MD
Ophthalmology · South Miami, FLNPI 1548431315
Payments from drug & device makers
Across 364 payments — averaging $37.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$5K
- Alcon$2K
- AbbVie$2K
- Oyster Point Pharma, Inc.$665
- Harrow Eye, LLC$459
- Sight Sciences, Inc.$402
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$3,10023%
- Food & beverage$10,32477%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 26 | $4,850 |
| Alcon | 54 | $2,405 |
| AbbVie(2 entities) | 108 | $2,120 |
| Oyster Point Pharma, Inc. | 45 | $665 |
| Harrow Eye, LLC | 22 | $459 |
| Sight Sciences, Inc. | 11 | $402 |
| Sun Pharmaceutical Industries Inc. | 25 | $398 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $372 |
| Bausch & Lomb Americas Inc. | 14 | $344 |
| Aerie Pharmaceuticals, Inc. | 14 | $336 |
| Glaukos Corporation | 9 | $287 |
| Amgen | 2 | $121 |
| Novartis | 6 | $117 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $109 |
| Tarsus Pharmaceuticals, Inc. | 4 | $93 |
| Beaver-visitec International, Inc. | 1 | $91 |
| Ocular Therapeutix, Inc. | 3 | $66 |
| Astellas Pharma US Inc | 2 | $61 |
| Medline Industries LP | 1 | $36 |
| Biotissue Holdings Inc. | 2 | $31 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Eyevance Pharmaceuticals LLC | 1 | $26 |
| Thea Pharma Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Omeros Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$4,300
- Ahmed Glaucoma Valve$4,300
- Clearpath$3,880
- Streamline$3,880
- Via360$1,919
- Tecnis IOL$535
- Streamline Surgical System$420
- Clareon$413
- Hydrus Microstent$396
- PanOptix$146
- Rhopressa$119
- Rocklatan$119
- iStent infinite Trabecular Micro-Bypass System Model iS3$118
- iAccess Precision Blade$118
- iStent Inject Trabecular Micro-Bypass System$118
- TEPEZZA$107
- Luxor$106
- XEN$100
How this compares
$13,469 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 1,072 | $422,988 |
| RestasisCyclosporine | 194 | $183,558 |
| CombiganBrimonidine Tartrate/Timolol | 451 | $162,981 |
| DurystaBimatoprost | 36 | $131,370 |
| IlevroNepafenac | 354 | $130,055 |
| Alphagan PBrimonidine Tartrate | 384 | $123,406 |
| VyzultaLatanoprostene Bunod | 284 | $112,202 |
| RocklatanNetarsudil Mesylat/Latanoprost | 168 | $78,540 |
| XiidraLifitegrast | 70 | $72,389 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 354 | $45,154 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 194 | $43,262 |
| MoxifloxacinMoxifloxacin Hcl | 866 | $38,287 |
| Prednisolone Acetate | 1,147 | $30,603 |
| XdemvyLotilaner | 13 | $23,480 |
| Brimonidine Tartrate | 666 | $23,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Durysta, Alphagan P | $2,120 | $1,024,3042,137 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $344 | $184,592354 claims |
| NovartisIlevro | $117 | $130,055354 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $336 | $101,447214 claims |
| AlconSimbrinza | $2,405 | $43,262194 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $93 | $23,48013 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $109 | $22,60364 claims |
| Harrow Eye, LLCVevye | $459 | $8,03211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in South Miami
- Zachary SegalSouth Miami$1.1M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.